Nemysis is an innovative pharmaceutical company focused on bioactive substances and delivering effective solutions to unmet patient needs. With a highly experienced and successful team of pharmaceutical executives and entrepreneurs, Nemysis has a track record of delivering projects together in previous ventures. Formed in 2017, Nemysis operates as an Irish company with virtual operations and staff distributed worldwide.

The company's therapeutic focus is on nutritional deficiencies, particularly minimizing gastrointestinal and other side effects caused by current available solutions. They have developed a diversified, independent platform with multi-product capabilities, with a specific emphasis on preserving the microbiome. One of their key products is IHAT – Nano Fe(III), a nanotechnology-based compound that addresses the effects of iron deficiency.

They have also developed E40, a new Glutenase specifically designed for Celiac Disease and Non-Celiac Gluten Sensitivity. Nemysis operates through various stages of product development, from scouting to distribution, and aims to take their compounds to drug status for the prescriptions market. Their goal is to create long-term relationships with stakeholders in the medical/bio-pharma research field and to commercialize novel technologies that are effective and gentle on the patients' gut microbiome